SARS-COV-2 – НОВЫЙ ФАКТОР РИСКА РАЗВИТИЯ ПРЕЭКЛАМПСИИ

Цель – оценка риска развития преэклампсии у беременных, инфицированных SARS-CoV-2, по результатам анализа за 2021 г. историй течения беременности и исходов родов 1 122 родоразрешенных женщин 3 групп: 52 беременных с подтвержденным SARS-CoV-2 и развившейся преэклампсией; 302 беременных с неподтвержденной инфекцией SARS-CoV-2 и развившейся преэклампсией; 768 беременных с подтвержденным SARS-CoV-2 и без преэклампсии. В группе пациенток с подтвержденным SARS-CoV-2 и развившейся преэклампсией в 2,5 раза чаще преобладала хроническая артериальная гипертензия по сравнению с беременными с преэклампсией с неподтвержденной инфекцией SARS-CoV-2 и в 10,4 раза – по сравнению с беременными без преэклампсии с подтвержденным SARS-CoV-2. Кроме того, вспомогательные репродуктивные технологии применялись чаще в 7,9 и 11,8 раз в группе беременных с подтвержденным SARS-CoV-2 и развившейся преэклампсией, чем в двух других группах беременных соответственно.
Преждевременные роды, преждевременная отслойка нормально расположенной плаценты, родоразрешение путем кесарева сечения, асфиксия новорожденных чаще осложняли исходы родов в группах с преэклампсией.

1. Chen M., Zeng J., Liu X. et al. Changes in physiology and immune system during pregnancy and coronavirus infection: A review. Eur J Obstet Gynecol Reprod Biol. 2020;255:124–128.

2. Vousden N., Bunch K., Knight M. et al. Incidence, risk factors and impact of seasonal influenza in pregnancy: A national cohort study. PLoS One. 2021;16(1):e0244986.

3. Dawood F. S., Kittikraisak W., Patel A. et al. Incidence of influenza during pregnancy and association with pregnancy and perinatal outcomes in three middle-income countries: A multisite prospective longitudinal cohort study. Lancet Infect Dis. 2021;21(1):97–106.

4. Villar J., Ariff S., Gunier R. B. et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr. 2021;175(8):817–826.

5. Di Mascio D., Khalil A., Saccone G. et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: A systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020;2(2):100107.

6. Conde-Agudelo A., Romero R. SARS-COV-2 infection during pregnancy and risk of preeclampsia: A systematic review and meta-analysis. Am J Obstet Gynecol. 2022;226(1):68–89.e3.

7. Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. London: RCOG Press; 2010. 288 p.

8. Committee opinion No. 638: First-trimester risk assessment for early onset preeclampsia. Obstet Gynecol. 2015;126(3):e25–e27.

9. Sotiriadis A., Hernandez-Andrade E., da Silva Costa F. et al. ISUOG Practice Guidelines: Role of ultrasound in screening for and follow-up of pre eclampsia. Ultrasound Obstet Gynecol. 2019;53(1):7–22.

10. Torres-Torres J., Martinez-Portilla R. J., Espino-Y-Sosa S. et al. Comorbidity, poverty and social vulnerability as risk factors for mortality in pregnant women with confirmed SARS-CoV-2 infection: Analysis of 13 062 positive pregnancies including 176 maternal deaths in Mexico. Ultrasound Obstet Gynecol. 2022;59(1):76–82.

11. Allotey J., Stallings E., Bonet M. et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. BMJ. 2020;370:m3320.

12. Papageorghiou A. T., Deruelle P., Gunier R. B. et al. Preeclampsia and COVID-19: Results from the INTERCOVID Prospective Longitudinal Study. Am J Obstet Gynecol. 2021;225(3):289.e1–289.e17.

13. Coronado-Arroyo J. C., Concepción-Zavaleta M. J., Zavaleta-Gutiérrez F. E. et al. Is COVID-19 a risk factor for severe preeclampsia? Hospital experience in a developing country. Eur J Obstet Gynecol Reprod Biol. 2021;256:502–503.

14. Gheblawi M., Wang K., Viveiros A. et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–1474.

15. Bhalla V., Blish C. A., South A. M. A historical perspective on ACE2 in the COVID-19 era. J Hum Hypertens. 2021;35(10):935–939.

16. Cui D., Liu Y., Jiang X. et al. Single-cell RNA expression profiling of SARS-CoV-2-related ACE2 and TMPRSS2 in human trophectoderm and placenta. Ultrasound Obstet Gynecol. 2021;57(2):248–256.

17. Hecht J. L., Quade B., Deshpande V. et al. SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. Mod Pathol. 2020;33(11):2092–2103.

18. Torres-Torres J., Espino-y-Sosa S., Poon L. C. et al. Increased levels of soluble fms-like tyrosine kinase-1 are associated with adverse outcome in pregnant women with COVID-19. Ultrasound Obstet Gynecol. 2022;59(2):202–208.

19. Todros T., Masturzo B., De Francia S. COVID-19 infection: ACE2, pregnancy and preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2020;253:330.

20. Bloise E., Zhang J., Nakpu J. et al. Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia. Am J Obstet Gynecol. 2021;224(3):298.e1–298.e8.

21. Ouyang Y., Bagalkot T., Fitzgerald W. et al. Term human placental trophoblasts express SARS-CoV-2 entry factors ACE2, TMPRSS2, and Furin. mSphere. 2021;6(2):e00250-21.

22. Taglauer E., Benarroch Y., Rop K. et al. Consistent localization of SARS-CoV-2 spike glycoprotein and ACE2 over TMPRSS2 predominance in placental villi of 15 COVID-19 positive maternal-fetal dyads. Placenta. 2020;100:69–74.

23. Argueta L. B., Lacko L. A., Bram Y. et al. SARS-CoV-2 infects syncytiotrophoblast and activates inflammatory responses in the placenta. bioRxiv. 2021. DOI 10.1101/2021.06.01.446676.

24. Verma S., Joshi C. S., Silverstein R. B. et al. SARS-CoV-2 colonization of maternal and fetal cells of the human placenta promotes alteration of local renin-angiotensin system. Med. 2021;2(5):575–590.e5.

25. Rana S., Lemoine E., Granger J. P. et al. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094–1112.

26. Beys-da-Silva W. O., da Rosa R. L., Santi L. et al. The risk of COVID-19 for pregnant women: Evidences of molecular alterations associated with preeclampsia in SARS-CoV-2 infection. Biochim Biophys Acta Mol Basis Dis. 2021;1867(3):165999.

27. Giuliani F., Oros D., Gunier R. B. et al. Effects of prenatal exposure to maternal COVID-19 and perinatal care on neonatal outcome: Results from the INTERCOVID Multinational Cohort Study. Am J Obstet Gynecol. 2022;227(3):488.e1–488.e17.